伊利利利的减肥药物Mounjaro和Zepbound在市场增长中为股票增长做出贡献, Eli Lilly's weight loss drugs Mounjaro and Zepbound contribute to stock rise amid market growth to $100bn by 2030.

礼来公司（Eli Lilly）的股价因成功的减肥药Mounjaro和Zepbound而上涨，面临来自诺和诺德（Novo Nordisk）的竞争。 Eli Lilly's stock has risen due to successful weight loss drugs Mounjaro and Zepbound, facing competition from Novo Nordisk. Pfizer不是在减肥市场上,它正在研制一种每天一次的口头配方,配方为danuglipron。 Pfizer, not in the weight loss market, is developing a once-daily oral formulation of danuglipron. 尽管辉瑞的药物还有很长的路要走，但预计到2030年，该市场将达到1000亿美元，多家公司有成功的空间。 Although Pfizer's drug has a long way to go, the market is expected to reach $100bn by 2030, with room for multiple companies to succeed. 莉莉目前从减重药物和导致商业化的药物获得的收入应继续推动增长。 Lilly's current revenue from its weight loss drugs and lead in commercialization should continue to drive growth.